Skip to content
Business

Novartis MS Pill Remibrutinib Beats Rival Drug in Two Late-Stage Trials

Novartis said its oral BTK inhibitor remibrutinib cut relapses more than Sanofi's teriflunomide in two Phase III trials of about 2,000 MS patients, with no liver safety signal.

Novartis scientists in white coats working at automated laboratory equipment in the Banting 1 research building in Basel.
Photo: Novartis

Novartis said on Tuesday that its multiple sclerosis pill remibrutinib cut relapse rates significantly more than teriflunomide, an established oral treatment, in two large Phase III trials. The Swiss drugmaker reported no liver safety signal, the problem that has held back rival drugs in the same class.

Two Trials, One Clear Result

The Basel-based group published topline results from the REMODEL-1 and REMODEL-2 studies early on 1 September in an ad hoc announcement, the disclosure Swiss listing rules require for price-sensitive news. The two identical trials enrolled about 2,000 adults with relapsing multiple sclerosis and recent disease activity, assigned in equal numbers to remibrutinib 100 mg or teriflunomide, the drug Sanofi sells as Aubagio.

Both studies met their primary endpoint, a significant reduction in the annualised relapse rate against teriflunomide. Novartis said remibrutinib was also superior on all key secondary endpoints in each trial, including the number of new or enlarging lesions seen on MRI brain scans. Patients were followed in a double-blind core phase of up to 30 months, with an open-label extension of up to five years.

On disability, the results were less clear-cut. A preplanned combined analysis of the two trials showed a positive trend in disability progression confirmed after three months, and nominal significance for progression confirmed after six months. Novartis described the effect as clinically meaningful but did not publish relapse rates, lesion counts or other figures.

What Novartis reported

  • Both Phase III trials met the main goal: fewer relapses per year than on teriflunomide
  • Superior on key secondary endpoints in each trial, including MRI lesions
  • Disability: positive trend at three months, nominal significance at six months, in pooled data
  • No liver safety signal and no cases meeting Hy's Law criteria
  • Plans to seek approval in relapsing MS worldwide; detailed data due at MSToronto2026

Novartis: share price, chart and news

Portrait of Shreeram Aradhye, Novartis President of Development and Chief Medical Officer, in a dark jacket outdoors.
Portrait of Shreeram Aradhye, Novartis President of Development and Chief Medical Officer, in a dark jacket outdoors. Photo: Novartis

The Liver Question Hanging Over BTK Drugs

Remibrutinib belongs to a class of medicines that block Bruton's tyrosine kinase, or BTK, an enzyme involved in the immune cells thought to drive damage in multiple sclerosis. The class has been one of the most closely watched areas of neurology, and also one of the most troubled.

Sanofi's tolebrutinib missed its goals in relapsing MS, looked more effective in a less common progressive form of the disease, and was rejected in the United States before winning approval in Europe in June. Merck KGaA's evobrutinib stumbled in testing. Liver-related side effects slowed both programmes, and analysts have questioned whether regulators will approve Roche's fenebrutinib for the same reason.

That is why the safety line in Tuesday's statement matters as much as the efficacy result. Novartis said the drug was well tolerated, that safety was consistent with a development programme covering more than 4,500 trial participants, and that there were no cases meeting Hy's Law criteria, the standard regulators use to flag a drug's potential to cause serious liver injury.

Already on the Market for Chronic Hives

Remibrutinib is not new to regulators. A 25 mg dose is approved under the brand name Rhapsido for chronic spontaneous urticaria, a long-lasting form of hives. The US Food and Drug Administration cleared it in September 2025 and European approval followed in April 2026, according to Novartis.

The multiple sclerosis trials used a higher 100 mg dose, so the earlier approvals do not settle the question on their own. But Novartis says the whole remibrutinib programme, now including roughly 2,000 MS patients in trials with a blinded phase of up to 30 months, has shown no liver safety signal. If the detailed data bear that out, it would be a stronger safety case than its rivals have been able to make.

Novartis already has a large presence in multiple sclerosis. An oral drug that beat an established pill on relapses in two trials, and that avoids the liver problems seen elsewhere in its class, would give the company a new product in a market where patients and doctors weigh convenience against efficacy.

What Happens Next

Novartis said it plans to file for approval of remibrutinib in relapsing multiple sclerosis around the world. Detailed results will be presented as a late-breaking abstract at the MSToronto2026 congress, and the company intends to host an investor call after that presentation.

Those numbers will decide how the drug is positioned. The size of the relapse reduction against teriflunomide, the strength of the disability data and the full liver safety tables are what doctors, regulators and investors will scrutinise, because teriflunomide is an older, moderate-efficacy pill rather than one of the antibody therapies used for more active disease.

For now, the read-across for the sector is twofold: Novartis has a credible new growth driver in neurology, and the pressure on rival BTK programmes to show comparable liver safety has increased.

Sources

Related stories

Markets

Novartis Suffers Its Worst Day on Record, Down 10.9%, After Two Late-Stage Trial Failures

Novartis fell 10.89% to CHF 111.80 on 8 September, its worst day on record, after del-desiran, the lead drug from its $12bn Avidity deal, missed its main goal, days after…

Markets

Novartis Sinks 13.5% on Twin Trial Failures as Brent Breaks $100 and the ECB Hikes

Novartis fell 13.54% in the week to 11 September after two late-stage trial failures, while Brent jumped 8.65% to $104.61 a barrel and the ECB raised rates for the second time this…

Markets

Novartis Raises Its Profit Outlook Despite a $1.9bn Writedown on Del-desiran

Novartis raised its 2026 profit guidance as Q3 core operating income rose 10% to $6.04bn, beating the $5.51bn expected, even as a $1.9bn del-desiran writedown cut reported profit…

Business

Russia Seizes Control of Nestlé's Local Business by Presidential Decree

A Russian presidential decree has put Nestlé Russia, with six factories and about 7,000 staff, under temporary external administration. Nestlé says it will act to protect its…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…